Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts.

Weiss SA, Han J, Darvishian F, Tchack J, Han SW, Malecek K, Krogsgaard M, Osman I, Zhong J.

J Transl Med. 2016 Oct 19;14(1):299.

2.

Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways.

Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

J Natl Cancer Inst. 2016 Feb 8;108(7). pii: djw004. doi: 10.1093/jnci/djw004. Print 2016 Jul.

3.

Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach.

Kim E, Rebecca V, Fedorenko IV, Messina JL, Mathew R, Maria-Engler SS, Basanta D, Smalley KS, Anderson AR.

Cancer Res. 2013 Dec 1;73(23):6874-85. doi: 10.1158/0008-5472.CAN-13-1720. Epub 2013 Sep 30.

4.
5.

Association between cutaneous melanoma incidence rates among white US residents and county-level estimates of solar ultraviolet exposure.

Richards TB, Johnson CJ, Tatalovich Z, Cockburn M, Eide MJ, Henry KA, Lai SM, Cherala SS, Huang Y, Ajani UA.

J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S50-7. doi: 10.1016/j.jaad.2011.04.035.

6.

Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?

Göppner D, Leverkus M.

J Skin Cancer. 2011;2011:521947. doi: 10.1155/2011/521947. Epub 2011 Oct 11.

7.

Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.

Kvaskoff M, Whiteman DC, Zhao ZZ, Montgomery GW, Martin NG, Hayward NK, Duffy DL.

Twin Res Hum Genet. 2011 Oct;14(5):422-32. doi: 10.1375/twin.14.5.422.

8.

The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.

Whiteman DC, Pavan WJ, Bastian BC.

Pigment Cell Melanoma Res. 2011 Oct;24(5):879-97. doi: 10.1111/j.1755-148X.2011.00880.x. Epub 2011 Aug 16. Review.

9.

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site.

Bauer J, Büttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, Scolyer RA, Bastian BC.

Pigment Cell Melanoma Res. 2011 Apr;24(2):345-51. doi: 10.1111/j.1755-148X.2011.00837.x.

10.

Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility.

Camilli TC, Xu M, O'Connell MP, Chien B, Frank BP, Subaran S, Indig FE, Morin PJ, Hewitt SM, Weeraratna AT.

Pigment Cell Melanoma Res. 2011 Feb;24(1):175-86. doi: 10.1111/j.1755-148X.2010.00792.x. Epub 2010 Dec 1.

11.

Primary cutaneous adenoid cystic carcinoma in the United States: incidence, survival, and associated cancers, 1976 to 2005.

Dores GM, Huycke MM, Devesa SS, Garcia CA.

J Am Acad Dermatol. 2010 Jul;63(1):71-8. doi: 10.1016/j.jaad.2009.07.027. Epub 2010 May 5.

12.

Melanoma epidemiology.

Tucker MA.

Hematol Oncol Clin North Am. 2009 Jun;23(3):383-95, vii. doi: 10.1016/j.hoc.2009.03.010. Review.

13.

Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells.

Slominski A, Zbytek B, Slominski R.

Int J Cancer. 2009 Mar 15;124(6):1470-7. doi: 10.1002/ijc.24005.

14.

Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis.

Olsen CM, Zens MS, Stukel TA, Sacerdote C, Chang YM, Armstrong BK, Bataille V, Berwick M, Elwood JM, Holly EA, Kirkpatrick C, Mack T, Bishop JN, Østerlind A, Swerdlow AJ, Zanetti R, Green AC, Karagas MR, Whiteman DC.

Int J Cancer. 2009 Feb 15;124(4):937-44. doi: 10.1002/ijc.24011.

Supplemental Content

Support Center